Answers are grounded in this paper and cite their sources.
Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.).
No takes yet. Share an insight, caveat, or question.
Choueiri et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: